Ideaya Biosciences Inc. (IDYA)
NASDAQ
Real-time Data
01:30 PM
Day's Range
40.0652 wk Range
23.23Overview - IDYA - Ideaya Biosciences Inc.
Key Statistics
Valuation
Enterprise Value
3.02B
P/E (Trailing)
‪-33.19‬
P/E (Forward)
‪-9.65‬
PEG Ratio
‪-0.85‬
Price / Sales (TTM)
‪16.34‬
Price / Book
‪3.18‬
EV / EBITDA
‪-14.13‬
Profitability
Profit Margin
‪-74.75%‬
Operating Margin
‪-1,380.72%‬
Return on Assets
‪-11.53%‬
Return on Equity
‪-16.21%‬
Ownership
Shares Outstanding
96.27M
Float
90.63M
Short % of Shares Outstanding
‪12.21%‬
Held by Insiders
‪2.19%‬
Held by Institutions
‪108.17%‬
Price stats
Beta
‪-0.09‬
50-Day Avg
‪35.91‬
200-Day Avg
‪33.27‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
15 analysts
Average price target
‪$ 52.15‬Shariah Compliance
Report Date: Feb 17, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - IDYA - Ideaya Biosciences Inc.
Peers - IDYA - Ideaya Biosciences Inc.
Peer Comparison
Compared with companies in Biotechnology listed on NASDAQ.
- IDYANASDAQIdeaya Biosciences Inc.4.09BMarket Cap+41.15%52-week change-33.20P/E (Trailing)‪-74.75%‬Profit Margin
- ARGXNASDAQargenx SE American Depositary Receipt63.39BMarket Cap+30.55%52-week change39.65P/E (Trailing)‪32.26%‬Profit Margin
- ALNYNASDAQAlnylam Pharmaceuticals Inc32.12BMarket Cap-87.94%52-week change40.23P/E (Trailing)‪16.12%‬Profit Margin
- BNTXNASDAQBioNTech SE28.64BMarket Cap+7.89%52-week change160.80P/E (Trailing)‪-63.63%‬Profit Margin
- ASNDNASDAQAscendis Pharma A/S16.52BMarket Cap+21.81%52-week change19.30P/E (Trailing)‪70.84%‬Profit Margin
- BBIONASDAQBridgeBio Pharma, Inc.15.71BMarket Cap+38.32%52-week change-21.28P/E (Trailing)‪-97.02%‬Profit Margin
- BMRNNASDAQBiomarin Pharmaceutical Inc.12.79BMarket Cap+11.28%52-week change174.00P/E (Trailing)‪2.14%‬Profit Margin
Profile Summary - IDYA - Ideaya Biosciences Inc.
About
Ideaya Biosciences Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations identified through molecular diagnostics. Its pipeline features IDE196, a protein kinase C inhibitor in Phase 2/3 clinical trials for cancers with GNAQ or GNA11 mutations; IDE397,…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
